Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.

Abstract:

INTRODUCTION:The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases. Many autoimmune diseases occur in women of child-bearing age who may become pregnant while on therapy, which raises concerns regarding the teratogenicity of HCQ and its effect on the outcome of the pregnancy. There is a lack of data regarding the safety of HCQ during pregnancy. AREAS COVERED:In this review, the authors attempt to identify relevant publications by searching MEDLINE, Cochrane database, Ovid-Currents Clinical Medicine, Ovid-Embase:Drugs and Pharmacology, EBSCO, Web of Science and SCOPUS using the search terms HCQ and/or pregnancy. A basis for the mechanism of action of HCQ is provided. EXPERT OPINION:HCQ has been shown by numerous studies over the past 15 years to be efficacious in the treatment of autoimmune diseases, including systemic lupus erythematosus, discoid lupus erythematosus and rheumatoid arthritis. HCQ does not appear to be associated with any increased risk of congenital defects, spontaneous abortions, fetal death, prematurity or decreased numbers of live births in patients with autoimmune diseases. Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy.

journal_name

Expert Opin Drug Saf

authors

Abarientos C,Sperber K,Shapiro DL,Aronow WS,Chao CP,Ash JY

doi

10.1517/14740338.2011.566555

subject

Has Abstract

pub_date

2011-09-01 00:00:00

pages

705-14

issue

5

eissn

1474-0338

issn

1744-764X

journal_volume

10

pub_type

杂志文章,评审
  • Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.

    abstract::The epidemiology, natural history and efficacy of treatment for chronic hepatitis C in children are presented. An increase in the number of vertical infections of this etiology is suggested. In children, especially in those vertically infected, spontaneous elimination of hepatitis C virus (HCV) is observed more often ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2015.1005599

    authors: Pawlowska M

    更新日期:2015-03-01 00:00:00

  • The safety of clopidogrel.

    abstract:IMPORTANCE OF THE FIELD:Clopidogrel is an antiplatelet prodrug widely used in acute coronary syndromes and after intravascular stent placement. Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy. AREAS COVERED IN THIS REVIEW:The mechani...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.532485

    authors: Mangalpally KK,Kleiman NS

    更新日期:2011-01-01 00:00:00

  • A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma.

    abstract:INTRODUCTION:Immune checkpoint inhibitors (ICIs) have rapidly changed the treatment landscape, demonstrating dramatic clinical efficacy in various cancers. AREAS COVERED:In urothelial cancer (UC), several ICIs have been approved in platinum refractory disease and also as first-line therapy in patients that fulfill the...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1792442

    authors: Economopoulou P,Kotsantis I,Bamias A

    更新日期:2020-08-01 00:00:00

  • Folic acid and cognition in older persons.

    abstract::Folic acid supplementation has drawn much attention in recent years for the prevention of Alzheimer's disease and cognitive decline. In this review, the authors describe how current evidence does not support the use of folic acid supplements to protect against cognitive decline. Although a few studies suggest that fol...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析

    doi:10.1517/14740338.5.4.511

    authors: Schneider JA,Tangney CC,Morris MC

    更新日期:2006-07-01 00:00:00

  • Risk of gastrointestinal bleeding during anticoagulant treatment.

    abstract:INTRODUCTION:Gastrointestinal bleeding (GIB) is a major problem in patients on oral anticoagulation therapy. This issue has become even more pressing since the introduction of direct oral anticoagulants (DOACs) in 2009. Areas covered: Here we review current evidence related to GIB associated with oral anticoagulants, f...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1325870

    authors: Lanas-Gimeno A,Lanas A

    更新日期:2017-06-01 00:00:00

  • How safe is rucaparib in ovarian cancer?

    abstract::Introduction: Rucaparib is increasingly being utilized for women with recurrent ovarian cancer both as treatment and maintenance therapy. Poly-ADP ribose polymerase (PARP) inhibitors like rucaparib are daily oral medication that exploit the DNA repair pathway. The most significant clinical benefit is in those tumors e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1550067

    authors: Cosgrove CM,O'Malley DM

    更新日期:2018-12-01 00:00:00

  • Adverse effects of antiretroviral therapy: focus on orofacial effects.

    abstract::The optimum anti-HIV drug has yet to be found. This paper will summarise some of the oral adverse effects associated with antiretroviral agents against HIV. The development of antiretroviral drugs for the treatment of HIV infection has been aimed at the inactivation of two HIV enzymes: reverse transcriptase and protea...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.1.4.307

    authors: Diz Dios P,Scully C

    更新日期:2002-11-01 00:00:00

  • Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding.

    abstract::Aspirin use is associated with gastroduodenal mucosal damage and increased risk of upper gastrointestinal (GI) bleeding. Many aspirin users should receive prophylactic treatment since they often have several risk factors for upper GI complications. The best therapeutic approach for reducing GI toxicity in low-dose asp...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.1.3.245

    authors: Lanas A,Ferrández A

    更新日期:2002-09-01 00:00:00

  • The safety of monoclonal antibodies for treatment of colorectal cancer.

    abstract:INTRODUCTION:Monoclonal antibodies such as bevacizumab, ramucirumab, cetuximab and panitumumab play an important role in the treatment of metastatic colorectal cancer (mCRC). With the introduction of these drugs considerable improvements in both progression-free survival (PFS) and overall survival (OS) were achieved. H...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2016.1167186

    authors: Berger MD,Lenz HJ

    更新日期:2016-06-01 00:00:00

  • Typical toxic components in traditional Chinese medicine.

    abstract:INTRODUCTION:Traditional Chinese medicine (TCM) is widely used around the world. However, with its wide use has been the identification of a number of toxicological issues that have severely restricted its use in clinical treatment. The identification of these toxic substances within TCM has become somewhat of a hot to...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.726610

    authors: Lv W,Piao JH,Jiang JG

    更新日期:2012-11-01 00:00:00

  • Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.

    abstract:INTRODUCTION:Brimonidine tartrate and brinzolamide eye drops are often used as third and fourth line treatment options to reduce intraocular pressure (IOP) in the management of glaucoma and ocular hypertension. Better tolerated, more effective topical agents requiring once daily instillation including prostaglandin ana...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1346083

    authors: Lusthaus JA,Goldberg I

    更新日期:2017-09-01 00:00:00

  • Thrombotic microangiopathy associated with gemcitabine: rare but real.

    abstract::Gemcitabine-associated thrombotic thrombocytopenic purpura is a rare complication of gemcitabine treatment with an incidence ranging from 0.015 to 1.4%. Clinically, this disease manifests as haemolytic anaemia, thrombocytopenia and renal insufficiency; hypertension and neurological and pulmonary symptoms are also know...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740330902942299

    authors: Saif MW,Xyla V,Makrilia N,Bliziotis I,Syrigos K

    更新日期:2009-05-01 00:00:00

  • The safety of available treatments options for neuroendocrine tumors.

    abstract:INTRODUCTION:Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to sum...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1354984

    authors: Faggiano A,Lo Calzo F,Pizza G,Modica R,Colao A

    更新日期:2017-10-01 00:00:00

  • Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review.

    abstract:INTRODUCTION:Secondary preventative therapies are essential for patients undergoing coronary artery bypass graft (CABG) surgery to optimize perioperative and long-term outcomes. Beta-blockers are commonly used to treat patients with coronary artery disease and congestive heart failure (CHF), but their role for CABG pat...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1504019

    authors: Thaper A,Kulik A

    更新日期:2018-08-01 00:00:00

  • An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

    abstract:BACKGROUND:The nasal cavity is a vulnerable zone which may be damaged by vascular disorders. We systematically assessed the frequency and severity of nasal cavity alterations during bevacizumab treatment, to determine its clinical relevance and factors contributing to its onset. PATIENTS AND METHODS:We conducted a hos...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2014.960388

    authors: D'Amico M,Pagano M,Pasa A,Puntoni M,Clavarezza M,Gennari A,Gozza A,Zanardi S,Defferrari C,Provinciali N,Campazzi E,Campora S,Paleari L,Marra D,Petrera M,DeCensi A

    更新日期:2014-11-01 00:00:00

  • The rational use of potentially hepatotoxic medications in patients with underlying liver disease.

    abstract::Given the fact that as many as 9% of all adverse drug reactions involve toxic effects on the liver and with upwards of 50% of all cases of fulminant hepatic failure being ascribed to acetaminophen and other agents, the safe use of medications takes on an even greater importance whenever the prescription of potentially...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.1.2.159

    authors: Lewis JH

    更新日期:2002-07-01 00:00:00

  • Osteonecrosis of the jaw: what do bisphosphonates do?

    abstract::Osteonecrosis of the jaw is a new disease, partly caused by bisphosphonates. It is commonly assumed that the bisphosphonates somehow cause cell death (osteocyte necrosis) within the jawbone, which makes it prone to chronic infection. In this article, an alternative pathogenetic theory is suggested, based on the normal...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.5.6.743

    authors: Aspenberg P

    更新日期:2006-11-01 00:00:00

  • Fixed-dose combinations banned in India: is it the right decision? An eye-opening review.

    abstract::Introduction: Fixed-dose combination (FDC) medicines contain more than one approved active pharmaceutical ingredient (API), are manufactured as a fixed-dose and packed in a single dosage form. FDCs have been drawing attention from the pharmaceutical industries because of the government's ban on 328 irrational FDCs in ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1651292

    authors: Miranda MRH,Dubey A,G S R,Charyulu RN

    更新日期:2019-10-01 00:00:00

  • Neuropsychiatric side effects of efavirenz therapy.

    abstract::The non-nucleoside analogue inhibitor of the reverse transcriptase, efavirenz (EFV), has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection. Although being effective in suppressing plasma viral load, neuropsychiatric side effects have been reported in individuals...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.6.2.147

    authors: Arendt G,de Nocker D,von Giesen HJ,Nolting T

    更新日期:2007-03-01 00:00:00

  • Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?

    abstract:INTRODUCTION:Nephrotoxicity is generally considered as the most clinically significant adverse reaction of amphotericin B, and has been reported in up to 80% of amphotericin B recipients during the first 2 weeks of treatment. Numerous experimental and clinical investigations have been performed over the past 4 decades,...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.721775

    authors: Karimzadeh I,Farsaei S,Khalili H,Dashti-Khavidaki S

    更新日期:2012-11-01 00:00:00

  • The safety of albiglutide for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1351538

    authors: Rendell MS

    更新日期:2017-09-01 00:00:00

  • Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.

    abstract:INTRODUCTION:In settings where HIV is prevalent in heterosexual populations, pregnancy and postpartum breastfeeding periods can be associated with substantial HIV acquisition risk. Pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF)/emtricitabine is an attractive HIV prevention option fo...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1338271

    authors: Mugwanya KK,John-Stewart G,Baeten J

    更新日期:2017-07-01 00:00:00

  • Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.

    abstract:INTRODUCTION:Clozapine was first introduced as an antipsychotic in the 1970's but a cluster of deaths, later linked to the drug's risk of agranulocytosis, led to its withdrawal in most countries. However, work in the 1980's established its unique efficacy in treatment resistant schizophrenia (TRS), which constitutes as...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1191468

    authors: Remington G,Lee J,Agid O,Takeuchi H,Foussias G,Hahn M,Fervaha G,Burton L,Powell V

    更新日期:2016-09-01 00:00:00

  • From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.

    abstract:BACKGROUND:To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travoprost) in patients previously treated with benzalkonium chloride (BAK)-preserved Latanoprost. METHODS:Cohort 6-month study on open-angle glaucoma or ocular hypertension patients. Complete ophthalmic examination, intraocular pr...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2015.1017467

    authors: Rossi GC,Scudeller L,Rolle T,Pasinetti GM,Bianchi PE

    更新日期:2015-05-01 00:00:00

  • Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.

    abstract::Objectives: Bullous pemphigoid, an autoimmune dermatological disease, may be associated with the use of a relatively new anti-cancer drug class, PD-1 inhibitors, which includes pembrolizumab and nivolumab. This paper analyzes the signals between PD-1 inhibitors and bullous pemphigoid based upon the reported real-world...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1619693

    authors: Aggarwal P

    更新日期:2019-07-01 00:00:00

  • Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Disease-modifying antirheumatic drugs (DMARDs) have significantly improved clinical symptoms and quality of life with reduced disease progression in many patients with rheumatoid arthritis (RA). Short-term glucocorticoid therapy is often used initially in combination with DMARDs, but some patients still ha...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1779219

    authors: Fleischmann R,Furst DE

    更新日期:2020-08-01 00:00:00

  • Efficacy and safety of mipomersen sodium (Kynamro).

    abstract:INTRODUCTION:Mipomersen is a first-in-class drug indicated as an adjunct to lipid-lowering medications and diet to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholes...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.793670

    authors: Hovingh K,Besseling J,Kastelein J

    更新日期:2013-07-01 00:00:00

  • Drug-induced parkinsonism.

    abstract:INTRODUCTION:Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease (iPD). Initially reported as a complication of antipsychotics, it was later recognized as a common complication of antidepressants, calcium channel antagonists, gastrointestinal prokinetics,...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.787065

    authors: López-Sendón J,Mena MA,de Yébenes JG

    更新日期:2013-07-01 00:00:00

  • Probiotics under the regulatory microscope.

    abstract::This review examines current knowledge regarding the safety of probiotic bacteria in man. Tighter and more comprehensive standards and regulations will be developed as probiotic therapy moves from a limited number of products used in the food industry, into more defined therapeutic categories and more complex organism...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.6.1135

    authors: Henriksson A,Borody T,Clancy R

    更新日期:2005-11-01 00:00:00

  • Risks and benefits of pre-operative dexmedetomidine in oral and maxillofacial surgeries: a systematic review.

    abstract:INTRODUCTION:Oral and maxillofacial surgeries might induce anxiety and pain to the patients. Sedative agents are one of the best ways for eliminating such consequences. Dexmedetomidine (DEX) is a recent sedative agent which presents higher sedative quality with greater specificity than other drugs. The aim of present p...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1323865

    authors: Davoudi A,Movahedian Attar B,Shadmehr E

    更新日期:2017-06-01 00:00:00